• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Pharmaceuticals - Scandinavia Industry Guide - Product Image

Pharmaceuticals - Scandinavia Industry Guide

  • Published: November 2012
  • Region: Scandinavia
  • 90 pages
  • MarketLine

Pharmaceuticals - Scandinavia Industry Guide is an essential resource for top-level data and analysis covering the Pharmaceuticals industry in each of the Scandinavian (Denmark, Norway and Sweden) countries. The report includes easily comparable data on market value, segmentation, and five forces analysis, plus full five year market forecasts for each country. It examines future problems, innovations and potential growth areas within the market.

Scope of the Report

- Contains an executive summary market values, and segmentation

- Provides textual analysis of the industry's prospects, competitive landscape and profiles of leading companies

- Incorporates in-depth five forces competitive environment analysis and scorecards

- Compares data from Denmark, Norway and Sweden, alongside individual chapters on each country. .

- Includes a five-year forecast of the industry

Highlights

The Scandinavian pharmaceuticals market had a total market value of $10.0 billion in 2011. Denmark was the fastest growing country with a CAGR of 4.7% over the 2007-11 period.

Within the pharmaceuticals industry, Sweden is the leading country among the READ MORE >

Introduction 8
What is this report about? 8
Who is the target reader? 8
How to use this report 8
Definitions 8
Scandinavia Pharmaceuticals Industry Outlook 9
Pharmaceuticals in Denmark 12
Market Overview 12
Market Data 13
Market Segmentation 14
Market outlook 16
Five forces analysis 17
Macroeconomic indicators 25
Pharmaceuticals in Norway 27
Market Overview 27
Market Data 28
Market Segmentation 29
Market outlook 31
Five forces analysis 32
Macroeconomic indicators 40
Pharmaceuticals in Sweden 42
Market Overview 42
Market Data 43
Market Segmentation 44
Market outlook 46
Five forces analysis 47
Macroeconomic indicators 55
Company Profiles 57
Leading companies 57
Appendix 89
Methodology 89

LIST OF TABLES
Table 1: Scandinavia pharmaceuticals industry, revenue ($bn), 2007-16 9
Table 2: Scandinavia pharmaceuticals industry, revenue ($bn), 2007-16 10
Table 3: Scandinavia pharmaceuticals industry forecast, revenue ($bn), 2011-16 11
Table 4: Denmark pharmaceuticals market value: $ billion, 2007–11 13
Table 5: Denmark pharmaceuticals market geography segmentation: $ billion, 2011 14
Table 6: Denmark pharmaceuticals market share: % share, by value, 2011 15
Table 7: Denmark pharmaceuticals market value forecast: $ billion, 2011–16 16
Table 8: Denmark size of population (million), 2007–11 25
Table 9: Denmark gdp (constant 2000 prices, $ billion), 2007–11 25
Table 10: Denmark gdp (current prices, $ billion), 2007–11 25
Table 11: Denmark inflation, 2007–11 26
Table 12: Denmark consumer price index (absolute), 2007–11 26
Table 13: Denmark exchange rate, 2007–11 26
Table 14: Norway pharmaceuticals market value: $ billion, 2007–11 28
Table 15: Norway pharmaceuticals market geography segmentation: $ billion, 2011 29
Table 16: Norway pharmaceuticals market share: % share, by value, 2011 30
Table 17: Norway pharmaceuticals market value forecast: $ billion, 2011–16 31
Table 18: Norway size of population (million), 2007–11 40
Table 19: Norway gdp (constant 2000 prices, $ billion), 2007–11 40
Table 20: Norway gdp (current prices, $ billion), 2007–11 40
Table 21: Norway inflation, 2007–11 41
Table 22: Norway consumer price index (absolute), 2007–11 41
Table 23: Norway exchange rate, 2007–11 41
Table 24: Sweden pharmaceuticals market value: $ billion, 2007–11 43
Table 25: Sweden pharmaceuticals market geography segmentation: $ billion, 2011 44
Table 26: Sweden pharmaceuticals market share: % share, by value, 2011 45
Table 27: Sweden pharmaceuticals market value forecast: $ billion, 2011–16 46
Table 28: Sweden size of population (million), 2007–11 55
Table 29: Sweden gdp (constant 2000 prices, $ billion), 2007–11 55
Table 30: Sweden gdp (current prices, $ billion), 2007–11 55
Table 31: Sweden inflation, 2007–11 56
Table 32: Sweden consumer price index (absolute), 2007–11 56
Table 33: Sweden exchange rate, 2007–11 56
Table 34: Pfizer Inc.: key facts 57
Table 35: Pfizer Inc.: key financials ($) 58
Table 36: Pfizer Inc.: key financial ratios 58
Table 37: GlaxoSmithKline Plc: key facts 60
Table 38: GlaxoSmithKline Plc: key financials ($) 61
Table 39: GlaxoSmithKline Plc: key financials (£) 62
Table 40: GlaxoSmithKline Plc: key financial ratios 62
Table 41: Orifarm A/S: key facts 64
Table 42: Pfizer Inc.: key facts 65
Table 43: Pfizer Inc.: key financials ($) 66
Table 44: Pfizer Inc.: key financial ratios 66
Table 45: GlaxoSmithKline Plc: key facts 68
Table 46: GlaxoSmithKline Plc: key financials ($) 69
Table 47: GlaxoSmithKline Plc: key financials (£) 70
Table 48: GlaxoSmithKline Plc: key financial ratios 70
Table 49: AstraZeneca PLC: key facts 72
Table 50: AstraZeneca PLC: key financials ($) 73
Table 51: AstraZeneca PLC: key financial ratios 74
Table 52: Johnson & Johnson: key facts 76
Table 53: Johnson & Johnson: key financials ($) 77
Table 54: Johnson & Johnson: key financial ratios 77
Table 55: Pfizer Inc.: key facts 79
Table 56: Pfizer Inc.: key financials ($) 80
Table 57: Pfizer Inc.: key financial ratios 80
Table 58: AstraZeneca PLC: key facts 82
Table 59: AstraZeneca PLC: key financials ($) 83
Table 60: AstraZeneca PLC: key financial ratios 84
Table 61: Novartis AG: key facts 86
Table 62: Novartis AG: key financials ($) 87
Table 63: Novartis AG: key financial ratios 87

LIST OF FIGURES
Figure 1: Scandinavia pharmaceuticals industry, revenue ($bn), 2007-16 9
Figure 2: Scandinavia pharmaceuticals industry, revenue ($bn), 2007-16 10
Figure 3: Scandinavia pharmaceuticals industry forecast, revenue ($bn), 2011-16 11
Figure 4: Denmark pharmaceuticals market value: $ billion, 2007–11 13
Figure 5: Denmark pharmaceuticals market geography segmentation: % share, by value, 2011 14
Figure 6: Denmark pharmaceuticals market share: % share, by value, 2011 15
Figure 7: Denmark pharmaceuticals market value forecast: $ billion, 2011–16 16
Figure 8: Forces driving competition in the pharmaceuticals market in Denmark, 2011 17
Figure 9: Drivers of buyer power in the pharmaceuticals market in Denmark, 2011 18
Figure 10: Drivers of supplier power in the pharmaceuticals market in Denmark, 2011 20
Figure 11: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Denmark, 2011 21
Figure 12: Factors influencing the threat of substitutes in the pharmaceuticals market in Denmark, 2011 23
Figure 13: Drivers of degree of rivalry in the pharmaceuticals market in Denmark, 2011 24
Figure 14: Norway pharmaceuticals market value: $ billion, 2007–11 28
Figure 15: Norway pharmaceuticals market geography segmentation: % share, by value, 2011 29
Figure 16: Norway pharmaceuticals market share: % share, by value, 2011 30
Figure 17: Norway pharmaceuticals market value forecast: $ billion, 2011–16 31
Figure 18: Forces driving competition in the pharmaceuticals market in Norway, 2011 32
Figure 19: Drivers of buyer power in the pharmaceuticals market in Norway, 2011 33
Figure 20: Drivers of supplier power in the pharmaceuticals market in Norway, 2011 35
Figure 21: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Norway, 2011 36
Figure 22: Factors influencing the threat of substitutes in the pharmaceuticals market in Norway, 2011 38
Figure 23: Drivers of degree of rivalry in the pharmaceuticals market in Norway, 2011 39
Figure 24: Sweden pharmaceuticals market value: $ billion, 2007–11 43
Figure 25: Sweden pharmaceuticals market geography segmentation: % share, by value, 2011 44
Figure 26: Sweden pharmaceuticals market share: % share, by value, 2011 45
Figure 27: Sweden pharmaceuticals market value forecast: $ billion, 2011–16 46
Figure 28: Forces driving competition in the pharmaceuticals market in Sweden, 2011 47
Figure 29: Drivers of buyer power in the pharmaceuticals market in Sweden, 2011 48
Figure 30: Drivers of supplier power in the pharmaceuticals market in Sweden, 2011 50
Figure 31: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Sweden, 2011 51
Figure 32: Factors influencing the threat of substitutes in the pharmaceuticals market in Sweden, 2011 53
Figure 33: Drivers of degree of rivalry in the pharmaceuticals market in Sweden, 2011 54
Figure 34: Pfizer Inc.: revenues & profitability 59
Figure 35: Pfizer Inc.: assets & liabilities 59
Figure 36: GlaxoSmithKline Plc: revenues & profitability 62
Figure 37: GlaxoSmithKline Plc: assets & liabilities 63
Figure 38: Pfizer Inc.: revenues & profitability 67
Figure 39: Pfizer Inc.: assets & liabilities 67
Figure 40: GlaxoSmithKline Plc: revenues & profitability 70
Figure 41: GlaxoSmithKline Plc: assets & liabilities 71
Figure 42: AstraZeneca PLC: revenues & profitability 74
Figure 43: AstraZeneca PLC: assets & liabilities 75
Figure 44: Johnson & Johnson: revenues & profitability 77
Figure 45: Johnson & Johnson: assets & liabilities 78
Figure 46: Pfizer Inc.: revenues & profitability 81
Figure 47: Pfizer Inc.: assets & liabilities 81
Figure 48: AstraZeneca PLC: revenues & profitability 84
Figure 49: AstraZeneca PLC: assets & liabilities 85
Figure 50: Novartis AG: revenues & profitability 88
Figure 51: Novartis AG: assets & liabilities 88

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos